RECENT DEVELOPMENTS IN TREATMENT OF PULMONARY DISEASES.

W. M. Kirby

1948-06-01

Abstract:O NE of the most important advances in chest diseases in recent years has been the advent of streptomycin in the treatment of pulmonary tuberculosis. Although its discovery was announced only four years ago, experience with over one thousand patients in Army, Navy, Veterans, and civilian hospitals has clearly demonstrated that streptomycin alters the course of tuberculous infections in a manner unapproached by earlier chemotherapeutic agents.3'7 Exudative infiltrations of recent origin represent the type of pulmonary lesion most favorably influenced by streptomycin. At this stage vascularity remains little impaired, and there is good penetlation of the antibiotic throughout the involved tissues. The most dramatic results are observed in miliary tuberculosis, in which there is frequently complete roentgenologic clearing of the pulmonary infiltrations. Relapses unfortunately occur in the majority of such patients, and a second course of treatment is ineffective because of the appearance of resistant organisms. Another reason for the poor results obtained in miliary tuberculosis is the high incidence of tuberculous meningitis, which may be present when treatment is started, or may develop two or three months later. With tuberculous meningitis the initial response to treatment is also usually good, but later the signs and symptoms recur and death results within a few weeks. Only about 15 per cent of patients with tuberculous meningitis have remained symptom free for as long as a year following therapy with streptomycin. Because of the development of resistant organisms, and the toxic potentialities of the drug, it is generally felt that streptomycin is not indicated at present in the treatment of patients with minimal and moderately advanced pulmonary tuberculosis, since in these stages the response to bed rest and collapse therapy is usually favorable. Streptomycin is also contraindicated in chronic fibroid or fibrocaseous tuberculosis, in which anatomical barriers prevent adequate contact between the infecting organisms and the antimicrobial agent. There may be regression of the infiltration surrounding long-standing fibrocaseous involvement, but improvement is usually slight and temporary. Tuberculous empyema is not benefited by streptomycin. Streptomycin also seems to be of value when used in conjunction with the surgical treatment of tuberculosis, especially resection. In the recent series of Clagett,2 streptomycin appeared to prevent early postoperative spreads following lobectomy and pneumonectomy. Late spreads, however, were not